Agency Information Collection Activities: Submission for OMB Review; Comment Request; Alzheimer's Disease Supportive Services Program-Data Reporting Tool, 36192-36193 [2013-14189]
Download as PDF
36192
Federal Register / Vol. 78, No. 116 / Monday, June 17, 2013 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention (CDC)
[CDC–2013–0009; Docket Number NIOSH–
264]
National Institute for Occupational
Safety and Health (NIOSH) Traumatic
Injury Research and Prevention
Program and Strategic Goals; Draft
Document Availability
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of draft document for
public comment.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC)
announces the availability of a draft
document entitled National Institute for
Occupational Safety and Health
(NIOSH) Traumatic Injury Research and
Prevention Program and Strategic Goals
now available for public comment. To
view the notice and related materials,
visit https://www.regulations.gov and
enter CDC–2013–0009 in the search
field and click ‘‘Search.’’
Public comment period: Comments
must be received September 16, 2013
from publication of the Federal Register
Notice.
ADDRESSES: You may submit comments,
identified by CDC–2013–0009 and
Docket Number NIOSH–264, by either
of the two following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: NIOSH Docket Office, Robert
A. Taft Laboratories, MS–C34, 4676
Columbia Parkway, Cincinnati, Ohio
45226.
Instructions: All information received
in response to this notice must include
the agency name and docket number
(CDC–2013–0009; NIOSH–264). All
relevant comments received will be
posted without change to https://
www.regulations.gov, including any
personal information provided. All
electronic comments should be
formatted as Microsoft Word. Please
make reference to CDC–2013–0009 and
Docket Number NIOSH–264.
SUPPLEMENTARY INFORMATION: The
purpose of this review is to receive
public comments and input on a draft
document entitled ‘‘NIOSH Traumatic
Injury Research and Prevention Program
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
20:38 Jun 14, 2013
Jkt 229001
and Strategic Goals.’’ This document
includes revisions to program strategic
goals last updated in 2009. The draft
strategic goals are intended to guide
NIOSH intramural and extramural
research for the 5-year period, 2014–
2019. NIOSH is seeking comments on:
(1) The relevance of the draft strategic
goals; (2) suggested areas where research
is needed or no-longer needed; (3) the
adequacy of the goals for addressing the
changing workplace and emerging
hazards that threaten the safety of
workers; (4) the adequacy of proposed
performance measures; (5) opportunities
for collaboration between NIOSH
scientists, extramural scientists, and
state occupational public health
programs; and (6) input on additional
potential partners the NIOSH Traumatic
Injury Program could work with to
enhance future directions of the NIOSH
Traumatic Injury Research and
Prevention Program.
Background: The strategic goals in the
Plan are largely based on fatal and
nonfatal surveillance data, and address
the following areas:
(1) Reduce Falls in the workplace
(2) Reduce Occupational Injuries and
Deaths due to Motor-Vehicle
Incidents and Crashes
(3) Reduce Occupational Injuries and
Deaths due to Workplace Violence
(4) Reduce Occupational Injuries and
Deaths due to Machines and
Industrial Vehicles
(5) Reduce Occupational Injuries and
Deaths among High Risk and
Vulnerable Worker Groups, and
(6) Increase use of Surveillance Data to
Guide Occupational Traumatic Injury
Research and Prevention Efforts.
FOR FURTHER INFORMATION CONTACT:
Dawn Castillo, NIOSH, Division of
Safety Research, Mailstop H–1900, 1095
Willowdale Road, Morgantown, West
Virginia 26505–2888. Ms. Castillo may
be contacted at (304) 285–5894 or Email
at DCastillo@cdc.gov.
Dated: June 7, 2013.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2013–14133 Filed 6–14–13; 8:45 am]
BILLING CODE 4163–19–P
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request;
Alzheimer’s Disease Supportive
Services Program—Data Reporting
Tool
Administration for Community
Living, HHS.
ACTION: Notice.
AGENCY:
The Administration on Aging
(AoA), Administration for Community
Living (ACL) is announcing an
opportunity to comment on the
proposed collection of information by
the agency. Under the Paperwork
Reduction Act of 1995 (the PRA),
Federal agencies are required to publish
notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice collects comments
on the information collection
requirements relating to the
continuation of an existing collection
for the Alzheimer’s Disease Supportive
Services Program.
DATES: Submit written comments on the
collection of information by August 16,
2013.
ADDRESSES: Submit written comments
on the collection of information by
email to Jane.Tilly@acl.hhs.gov
FOR FURTHER INFORMATION CONTACT: Jane
Tilly 202.357.3438
SUPPLEMENTARY INFORMATION: The
Alzheimer’s Disease Supportive
Services Program (ADSSP) is authorized
through Sections 398, 399 and 399A of
the Public Health Service (PHS) Act, as
amended by Public Law 101–557 Home
Health Care and Alzheimer’s Disease
Amendments of 1990. The ADSSP helps
state efforts to expand the availability of
community-level supportive services for
persons with Alzheimer’s disease and
their caregivers, including underserved
populations. In compliance with the
PHS Act, ACL revised an ADSSP Data
Reporting Tool (ADSSP–DRT) in 2010.
The ADSSP–DRT collects information
about the delivery of direct services by
ADSSP state grantees, as well as basic
demographic information about service
recipients. This version includes some
revisions to the approved 2010 version.
The revised version would be in effect
beginning 8/31/2013 and thereafter.
The proposed FY2013 ADSSP–DRT
can be found on AoA’s Web site at:
SUMMARY:
E:\FR\FM\17JNN1.SGM
17JNN1
36193
Federal Register / Vol. 78, No. 116 / Monday, June 17, 2013 / Notices
https://www.aoa.gov/AoARoot/AoA_
Programs/HPW/Alz_Grants/docs/
ADSSP_DataCollectionReportingForm_
proposed.xls.
ACL estimates the burden of this
collection of information as follows:
ANNUAL BURDEN ESTIMATES
Number of
respondents
Instrument
Type of respondent
ADSSP Data Reporting Tool ...........
ADSSP Data Reporting Tool ...........
Local Program Site ..........................
State Grantee ..................................
Estimated Total Annual Burden
Hours: 1176.
Dated: June 11, 2013.
Kathy Greenlee,
Administrator & Assistant Secretary for
Aging.
[FR Doc. 2013–14189 Filed 6–14–13; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0662]
Agency Information Collection
Activities: Proposed Collection;
Comment Request; Applications for
Food and Drug Administration
Approval To Market a New Drug:
Patent Submission and Listing
Requirements
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the reporting requirements for
submission and listing of patent
information associated with a new drug
application (NDA), an amendment, or a
supplement.
DATES: Submit either electronic or
written comments on the collection of
information by August 16, 2013.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
20:38 Jun 14, 2013
Jkt 229001
60
30
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: Ila
S. Mizrachi, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., P150–
400B, Rockville, MD 20850, 301–796–
7726, Ila.Mizrachi@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Responses
per
respondent
Burden
hours per
response
2
2
5.8
8
Total
burden
hours
(annual)
696
480
when appropriate, and other forms of
information technology.
Applications for FDA Approval To
Market a New Drug: Patent Submission
and Listing Requirements and
Application of 30-Month Stays on
Approval of Abbreviated New Drug
Applications Certifying That a Patent
Claiming a Drug Is Invalid or Will Not
Be Infringed—(OMB Control Number
0910–0513)—Extension
Section 505(b)(1) of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act)
(21 U.S.C. 355(b)(1)) requires all NDA
applicants to file, as part of the NDA,
‘‘the patent number and the expiration
date of any patent which claims the
drug for which the applicant submitted
the application or which claims a
method of using such drug and with
respect to which a claim of patent
infringement could reasonably be
asserted if a person not licensed by the
owner engaged in the manufacture, use,
or sale of the drug.’’ Section 505(c)(2) of
the FD&C Act (21 U.S.C. 355(c)(2))
imposes a similar patent submission
obligation on holders of approved NDAs
when the NDA holder could not have
submitted the patent information with
its application. Under section 505(b)(1)
of the FD&C Act, we publish patent
information after approval of an NDA in
the list entitled ‘‘Approved Drug
Products With Therapeutic Equivalence
Evaluations’’ (the Orange Book). If
patent information is submitted after
NDA approval, section 505(c)(2) of the
FD&C Act directs us to publish the
information upon its submission.
FDA regulations at §§ 314.50(h) (21
CFR 314.50(h)) and 314.53 (21 CFR
314.53) clarify the types of patent
information that must and must not be
submitted to FDA as part of an NDA, an
amendment, or a supplement, and
require persons submitting an NDA, an
amendment, or a supplement, or
submitting information on a patent after
NDA approval, to make a detailed
patent declaration using Forms FDA
3542 and 3542a.
The reporting burden for submitting
an NDA, an amendment, or a
supplement in accordance with § 314.50
E:\FR\FM\17JNN1.SGM
17JNN1
Agencies
[Federal Register Volume 78, Number 116 (Monday, June 17, 2013)]
[Notices]
[Pages 36192-36193]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14189]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Community Living
Agency Information Collection Activities: Submission for OMB
Review; Comment Request; Alzheimer's Disease Supportive Services
Program--Data Reporting Tool
AGENCY: Administration for Community Living, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Administration on Aging (AoA), Administration for
Community Living (ACL) is announcing an opportunity to comment on the
proposed collection of information by the agency. Under the Paperwork
Reduction Act of 1995 (the PRA), Federal agencies are required to
publish notice in the Federal Register concerning each proposed
collection of information, including each proposed extension of an
existing collection of information, and to allow 60 days for public
comment in response to the notice. This notice collects comments on the
information collection requirements relating to the continuation of an
existing collection for the Alzheimer's Disease Supportive Services
Program.
DATES: Submit written comments on the collection of information by
August 16, 2013.
ADDRESSES: Submit written comments on the collection of information by
email to Jane.Tilly@acl.hhs.gov
FOR FURTHER INFORMATION CONTACT: Jane Tilly 202.357.3438
SUPPLEMENTARY INFORMATION: The Alzheimer's Disease Supportive Services
Program (ADSSP) is authorized through Sections 398, 399 and 399A of the
Public Health Service (PHS) Act, as amended by Public Law 101-557 Home
Health Care and Alzheimer's Disease Amendments of 1990. The ADSSP helps
state efforts to expand the availability of community-level supportive
services for persons with Alzheimer's disease and their caregivers,
including underserved populations. In compliance with the PHS Act, ACL
revised an ADSSP Data Reporting Tool (ADSSP-DRT) in 2010. The ADSSP-DRT
collects information about the delivery of direct services by ADSSP
state grantees, as well as basic demographic information about service
recipients. This version includes some revisions to the approved 2010
version. The revised version would be in effect beginning 8/31/2013 and
thereafter.
The proposed FY2013 ADSSP-DRT can be found on AoA's Web site at:
[[Page 36193]]
https://www.aoa.gov/AoARoot/AoA_Programs/HPW/Alz_Grants/docs/ADSSP_DataCollectionReportingForm_proposed.xls.
ACL estimates the burden of this collection of information as
follows:
Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
Type of Number of Responses per Burden hours Total burden
Instrument respondent respondents respondent per response hours (annual)
----------------------------------------------------------------------------------------------------------------
ADSSP Data Reporting Tool.... Local Program 60 2 5.8 696
Site.
ADSSP Data Reporting Tool.... State Grantee... 30 2 8 480
----------------------------------------------------------------------------------------------------------------
Estimated Total Annual Burden Hours: 1176.
Dated: June 11, 2013.
Kathy Greenlee,
Administrator & Assistant Secretary for Aging.
[FR Doc. 2013-14189 Filed 6-14-13; 8:45 am]
BILLING CODE 4154-01-P